2013
Increased brain uptake and oxidation of acetate in heavy drinkers
Jiang L, Gulanski BI, De Feyter HM, Weinzimer SA, Pittman B, Guidone E, Koretski J, Harman S, Petrakis IL, Krystal JH, Mason GF. Increased brain uptake and oxidation of acetate in heavy drinkers. Journal Of Clinical Investigation 2013, 123: 1605-1614. PMID: 23478412, PMCID: PMC3613911, DOI: 10.1172/jci65153.Peer-Reviewed Original ResearchConceptsHeavy drinkersBrain uptakeN-acetylaspartateLight drinkersChronic heavy drinkingNew therapeutic approachesGreater brain uptakeAlcohol detoxificationConsequences of drinkingTherapeutic approachesMagnetic resonance spectroscopyMore brainHeavy drinkingDrinkersBrainWeeksBloodDrinksGlutamateDrinkingResonance spectroscopy
2004
ANTI-GLUTAMATE TREATMENTS FOR ALCOHOL DETOXIFICATION: A DOUBLE-BLIND PLACEBO-CONTROLLED PILOT STUDY OF LAMOTRIGINE, MEMANTINE, AND TOPIRAMATE.
Krupitsky E, Rudenko A, Burakov A, Zvartau E, Slavina T, Grinenko A, Krystal J. ANTI-GLUTAMATE TREATMENTS FOR ALCOHOL DETOXIFICATION: A DOUBLE-BLIND PLACEBO-CONTROLLED PILOT STUDY OF LAMOTRIGINE, MEMANTINE, AND TOPIRAMATE. Alcohol Clinical And Experimental Research 2004, 28: 50a. DOI: 10.1097/00000374-200408002-00258.Peer-Reviewed Original Research
1997
Evidence of acoustic startle hyperreflexia in recently detoxified early onset male alcoholics: modulation by yohimbine and m-Chlorophenylpiperazine (mCPP)
Krystal J, Webb E, Grillon C, Cooney N, Casal L, Morgan III. C, Southwick S, Davis M, Charney D. Evidence of acoustic startle hyperreflexia in recently detoxified early onset male alcoholics: modulation by yohimbine and m-Chlorophenylpiperazine (mCPP). Psychopharmacology 1997, 131: 207-215. PMID: 9203230, DOI: 10.1007/s002130050285.Peer-Reviewed Original ResearchConceptsHealthy subjectsAcoustic startle responseEthanol withdrawalStartle responseStartle magnitudeStartle amplitudeRandomized orderAcoustic startle magnitudeChronic alcoholic patientsSerotonin partial agonistDouble-blind conditionsAcoustic startle amplitudeNumber of episodesMale healthy subjectsΑ2-adrenergic antagonistTest dayMale patientsPlacebo dayAlcoholic patientsIntravenous infusionNoradrenergic functionYohimbine effectAlcohol detoxificationDrug infusionPreclinical studies